solifenacin succinate has been researched along with oxybutynin in 54 studies
| Studies (solifenacin succinate) | Trials (solifenacin succinate) | Recent Studies (post-2010) (solifenacin succinate) | Studies (oxybutynin) | Trials (oxybutynin) | Recent Studies (post-2010) (oxybutynin) |
|---|---|---|---|---|---|
| 522 | 194 | 343 | 2,607 | 619 | 1,670 |
| Protein | Taxonomy | solifenacin succinate (IC50) | oxybutynin (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.5951 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.002 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0032 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0035 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0027 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.5951 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.4288 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.792 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0855 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (38.89) | 29.6817 |
| 2010's | 30 (55.56) | 24.3611 |
| 2020's | 3 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, K; Ikeda, K; Kobayashi, S; Miyata, K; Suzuki, M; Takeuchi, M; Yamada, T | 1 |
| Ikeda, K; Kobayashi, S; Miyata, K | 1 |
| Hatanaka, T; Ikeda, K; Kobayashi, S; Miyata, K; Ohtake, A; Sasamata, M; Sato, S; Ukai, M | 1 |
| Sand, PK | 1 |
| Miyata, K; Oki, T; Sato, S; Yamada, S | 1 |
| Krivoborodov, GG; Mazo, EB | 1 |
| MacDiarmid, SA; Staskin, DR | 1 |
| Appell, RA; McCrery, RJ; Smith, PP | 1 |
| Oki, T; Takeuchi, C; Yamada, S | 1 |
| Brubaker, L; Chapple, C; Coyne, KS; Kopp, Z | 1 |
| Hegde, SS; Michel, MC | 1 |
| Hatanaka, T; Miyata, K; Noguchi, Y; Ohtake, A; Okutsu, H; Saitoh, C; Sasamata, M; Sato, S; Suzuki, M; Ukai, M; Yuyama, H | 1 |
| Cardozo, L; Cartwright, R; Robinson, D; Vella, M | 1 |
| Bertozzi, R; Cipriani, S; Colli, E; Meschia, M; Montorsi, F; Olivieri, L; Parazzini, F | 1 |
| Chugh, A; Gupta, JB; Hegde, LG; Kumar, N; Meru, AV; Naruganahalli, KS; Ray, A; Sinha, S | 1 |
| Hilas, O; Lam, S | 1 |
| Duggan, P; Wong, C | 1 |
| Brenes, FJ; Chapple, CR; Rosenberg, MT | 1 |
| Fujino, T; Ito, Y; Matsui, M; Noguchi, Y; Ohtake, A; Oyunzul, L; Sasamata, M; Suzuki, M; Yamada, S; Yoshida, A; Yuyama, H | 1 |
| Bolodeoku, J; Edgar, C; Tretter, RN; Wesnes, KA | 1 |
| Cardozo, L; Sidhu, M; Thorpe, A; Warner, J | 1 |
| Wyndaele, JJ | 1 |
| Barkin, J; Carlson, K; Drutz, H; Egerdie, B; Gajewski, JB; Herschorn, S; Paradiso-Hardy, F; Pommerville, P; Radomski, S; Schulz, J; Stothers, L | 1 |
| Herschorn, S; Piwko, C; Vicente, C | 1 |
| Fujino, T; Kageyama, A; Nozawa, Y; Yamada, S; Yoshida, A | 1 |
| Jakobsen, SM; Kersten, H; Molden, E | 1 |
| Bungay, PJ; Callegari, E; Fenner, KS; Kay, GG; Kempshall, S; LaPerle, JL; Malhotra, B; Michel, MC; Webster, R | 1 |
| Schröder, A; Thüroff, JW | 1 |
| Chess-Williams, R; Moro, C; Uchiyama, J | 1 |
| Cody, JD; Ellis, G; Hay-Smith, EJ; Herbison, GP; Madhuvrata, P | 1 |
| Kane, RL; Ramakrishnan, R; Sainfort, F; Shamliyan, T; Wyman, JF | 1 |
| Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL | 1 |
| Compion, G; Dale, M; Stow, B; Tretter, R; Wagg, A | 2 |
| Cornu, JN | 1 |
| Abrams, P; Hart, WM; Munro, V; Nazir, J; Retsa, P | 1 |
| Akino, H; Fujiuchi, Y; Fuse, H; Kitagawa, Y; Miyazawa, K; Namiki, M; Suzuki, K; Yokoyama, O | 1 |
| Kosilov, KV; Kosilova, LV; Krasnykh, MA; Loparev, SA | 1 |
| Blak, B; Hakimi, Z; Johnson, M; Nazir, J; Odeyemi, IA | 1 |
| Trivedi, D | 1 |
| Barkin, J; Berner, T; Diles, D; Franks, B | 1 |
| Hikiyama, E; Ito, Y; Kashiwabara, M; Onoue, S; Yamada, S; Yoshida, A | 1 |
| Hsiao, SM; Kuo, HC; Lin, HH | 1 |
| Ahamed, AA; Lim, V; Masten Singh, PK; Naidu, P; Nalliah, S; Wg, P | 1 |
| Dandolu, V; Lua, LL; Pathak, P | 1 |
| Aballéa, S; Hakimi, Z; Kelleher, C; Maman, K; Mankowski, C; Nazir, J; Odeyemi, I | 1 |
| Herbison, P; McKenzie, JE | 1 |
| Cetinel, B; Dincer, M; Gultekin, MH; Guzelsoy, M; Onal, B; Turegun, FA | 1 |
| Almeida, FG; Bernardo, WM; Sacomani, CAR; Silvinato, A | 1 |
| Hansson, F; Kilany, S; Milsom, I; Schiotz, HA; Svensson, M | 1 |
| Panicker, JN; Richardson, K; Welk, B | 1 |
| Gomes, T; Herschorn, S; Jarvi, K; Juurlink, D; Matta, R; Nam, RK | 1 |
| Hiren Prajapati, HP; Krunal Vishavadia, KV; Madhu Sharma, MS; Sandip Solanki, SS | 1 |
20 review(s) available for solifenacin succinate and oxybutynin
| Article | Year |
|---|---|
Elevating our therapeutic expectations in overactive bladder.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Incontinence; Vision Disorders; Xerostomia | 2004 |
[Neurological aspect of the hyperactive urinary bladder syndrome].
Topics: Benzilates; Brain; Brain Diseases; Cerebrovascular Circulation; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Parkinson Disease; Positron-Emission Tomography; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Neurogenic | 2005 |
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Incontinence | 2006 |
The emergence of new drugs for overactive bladder.
Topics: Acetylcholine; Amines; Animals; Anticonvulsants; Benzhydryl Compounds; Cresols; Cyclohexanecarboxylic Acids; Drug Evaluation, Preclinical; Gabapentin; gamma-Aminobutyric Acid; Humans; Mandelic Acids; Muscarinic Antagonists; Muscle, Smooth; Phenylpropanolamine; Product Surveillance, Postmarketing; Quinuclidines; Randomized Controlled Trials as Topic; Receptor, Muscarinic M3; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urinary Incontinence | 2006 |
Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Health Status; Humans; Mandelic Acids; Muscarinic Antagonists; Patient Compliance; Patient Satisfaction; Phenylpropanolamine; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Incontinence, Stress | 2006 |
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Parasympatholytics; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2006 |
New developments in the treatment of urinary incontinence.
Topics: Administration, Cutaneous; Adrenergic Uptake Inhibitors; Benzofurans; Drug Therapy, Combination; Duloxetine Hydrochloride; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrrolidines; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiophenes; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Stress | 2006 |
Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Topics: Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination | 2007 |
Update on drugs for overactive bladder syndrome.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Pharmacologic management of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.
Topics: Benzofurans; Drug Administration Schedule; Humans; Mandelic Acids; Multicenter Studies as Topic; Muscarinic Antagonists; Patient Satisfaction; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
New strategies for medical management of overactive bladder in children.
Topics: Benzhydryl Compounds; Benzilates; Botulinum Toxins; Child; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Quinuclidines; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination | 2010 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2012 |
Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Comparative Effectiveness Research; Cresols; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Incontinence | 2012 |
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; Humans; Imidazoles; Mandelic Acids; Muscarinic Antagonists; Nocturia; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2012 |
Cochrane Review Summary: Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women.
Topics: Clenbuterol; Combined Modality Therapy; Duloxetine Hydrochloride; Electric Stimulation; Exercise Therapy; Female; Hot Temperature; Humans; Mandelic Acids; Patient Satisfaction; Pelvic Floor; Solifenacin Succinate; Treatment Outcome; Urinary Incontinence; Urological Agents | 2015 |
Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis.
Topics: Dose-Response Relationship, Drug; Female; Humans; Mandelic Acids; Randomized Controlled Trials as Topic; Solifenacin Succinate; Urinary Bladder, Overactive; Urological Agents; Women's Health | 2017 |
Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Benzilates; Humans; Mandelic Acids; Muscarinic Antagonists; Network Meta-Analysis; Solifenacin Succinate; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2018 |
Which anticholinergic is best for people with overactive bladders? A network meta-analysis.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Humans; Imidazoles; Mandelic Acids; Network Meta-Analysis; Pyrrolidines; Solifenacin Succinate; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2019 |
The cognitive effect of anticholinergics for patients with overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cognition; Cognitive Dysfunction; Dementia; Humans; Mandelic Acids; Prodromal Symptoms; Pyrrolidines; Risk Assessment; Risk Factors; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2021 |
7 trial(s) available for solifenacin succinate and oxybutynin
| Article | Year |
|---|---|
Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
Topics: Adult; Aged; Cholinergic Antagonists; Female; Humans; Mandelic Acids; Middle Aged; Nocturia; Pilot Projects; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Failure; Urinary Bladder, Overactive | 2009 |
Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.
Topics: Aged; Attention; Cognition; Cognition Disorders; Cross-Over Studies; Executive Function; Female; Humans; Hypnotics and Sedatives; Learning; Male; Mandelic Acids; Memory; Memory, Short-Term; Muscarinic Antagonists; Neuropsychological Tests; Parasympatholytics; Pilot Projects; Quinuclidines; Reaction Time; Risk; Sample Size; Solifenacin Succinate; Tetrahydroisoquinolines | 2009 |
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Topics: Adult; Aged; Aged, 80 and over; Canada; Chi-Square Distribution; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia | 2010 |
Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.
Topics: Canada; Cost-Benefit Analysis; Female; Humans; Male; Mandelic Acids; Markov Chains; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2010 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Method; Female; Humans; Least-Squares Analysis; Male; Mandelic Acids; Memory; Muscarinic Antagonists; Quinuclidines; Risk Factors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive; Urological Agents | 2013 |
[Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
Topics: Aged; Benzhydryl Compounds; Benzilates; Cresols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2014 |
Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Topics: Adult; Aged; Benzhydryl Compounds; Benzilates; Benzofurans; Blood Pressure; Female; Heart Rate; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Nortropanes; Prospective Studies; Pyrrolidines; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2019 |
27 other study(ies) available for solifenacin succinate and oxybutynin
| Article | Year |
|---|---|
M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Topics: Animals; Benzofurans; Bradycardia; Calcium; Carbachol; Cells, Cultured; Cytosol; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; In Vitro Techniques; Isoquinolines; Kinetics; Male; Mandelic Acids; Mice; Mice, Inbred BALB C; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Pyrrolidines; Quinuclidines; Rats; Receptor, Muscarinic M3; Receptors, Muscarinic; Salivary Glands; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder | 2002 |
Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
Topics: Animals; Benzhydryl Compounds; Benzofurans; Calcium; Calcium Signaling; Carbachol; Cresols; Dose-Response Relationship, Drug; In Vitro Techniques; Inhibitory Concentration 50; Macaca fascicularis; Male; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Submandibular Gland; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder | 2004 |
In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzofurans; Calcium; Cresols; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Mandelic Acids; Muscarinic Antagonists; Myocytes, Smooth Muscle; Organ Specificity; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Rats; Rats, Wistar; Solifenacin Succinate; Submandibular Gland; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder | 2004 |
Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
Topics: Administration, Oral; Animals; Depression, Chemical; In Vitro Techniques; Male; Mandelic Acids; Mice; Muscarinic Antagonists; Quinuclidines; Radioligand Assay; Receptors, Muscarinic; Salivary Glands; Salivation; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder | 2005 |
Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.
Topics: Administration, Oral; Animals; Kinetics; Male; Mandelic Acids; Mice; Mice, Inbred Strains; Parasympatholytics; Quinuclidines; Receptors, Muscarinic; Saliva; Salivation; Solifenacin Succinate; Tetrahydroisoquinolines | 2006 |
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzilates; Benzofurans; Binding, Competitive; Carbachol; CHO Cells; Cholinergic Agonists; Cresols; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Mandelic Acids; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; N-Methylscopolamine; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Transfection; Urinary Bladder; Urinary Bladder, Overactive; Urination | 2007 |
Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model.
Topics: Anesthesia; Animals; Benzhydryl Compounds; Benzofurans; Carbachol; Cholinergic Antagonists; Cresols; Injections, Intra-Arterial; Male; Mandelic Acids; Phenylpropanolamine; Pressure; Pyrrolidines; Quinuclidines; Rabbits; Salivary Glands; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder | 2007 |
Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Male; Mandelic Acids; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Muscarinic Antagonists; Protein Binding; Quinuclidines; Radioligand Assay; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Solifenacin Succinate; Submandibular Gland; Tetrahydroisoquinolines; Urinary Bladder | 2009 |
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Topics: Benzhydryl Compounds; Benzilates; Cost-Benefit Analysis; Cresols; Decision Trees; Delayed-Action Preparations; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2010 |
Pediatrics: combining antimuscarinics shows promise for overactive bladder.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Pediatrics; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis.
Topics: Adenosine Triphosphate; Animals; Benzhydryl Compounds; Benzofurans; Cresols; Cystitis; Disease Models, Animal; Down-Regulation; Female; Hydrochloric Acid; Mandelic Acids; N-Methylscopolamine; Organophosphonates; Phenols; Phenylpropanolamine; Pirenzepine; Polycyclic Compounds; Pyridoxal Phosphate; Pyrrolidines; Quinuclidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Receptors, Purinergic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urination; Urodynamics | 2010 |
Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay.
Topics: Benzhydryl Compounds; Benzofurans; Biological Assay; Brain; Cognition Disorders; Cresols; Humans; In Vitro Techniques; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate | 2011 |
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Benzhydryl Compounds; Benzofurans; Blood-Brain Barrier; Brain; Cell Line; Chromatography, High Pressure Liquid; Cresols; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Solifenacin Succinate; Tandem Mass Spectrometry; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2011 |
Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzofurans; Carbachol; Cresols; Diamines; Mandelic Acids; Mucous Membrane; Muscarinic Antagonists; Muscle Contraction; Phenylpropanolamine; Piperidines; Pirenzepine; Pyrrolidines; Quinuclidines; Receptor, Muscarinic M3; Solifenacin Succinate; Stress, Mechanical; Swine; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urothelium | 2011 |
Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg.
Topics: Aging; Cognition; Cognitive Dysfunction; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urological Agents | 2013 |
Reply from authors re: Jean-Nicolas Cornu. Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg. Eur Urol 2013;64:82-3.
Topics: Aging; Cognition; Cognitive Dysfunction; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urological Agents | 2013 |
Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Cresols; Humans; Incontinence Pads; Mandelic Acids; Markov Chains; Medication Adherence; Models, Economic; Muscarinic Antagonists; Patient Dropouts; Phenylpropanolamine; Quality-Adjusted Life Years; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive; Urinary Incontinence | 2013 |
Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Benzilates; Cresols; Cross-Sectional Studies; Female; Humans; Imidazoles; Japan; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Benzhydryl Compounds; Cresols; Family Practice; Humans; Lower Urinary Tract Symptoms; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Primary Health Care; Prostatic Hyperplasia; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Tolterodine Tartrate; United Kingdom | 2015 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug Therapy, Combination; Humans; Longitudinal Studies; Male; Mandelic Acids; Medication Adherence; Middle Aged; Muscarinic Antagonists; Ontario; Prazosin; Prostatic Hyperplasia; Prostatism; Pyrrolidines; Quinazolines; Retrospective Studies; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tolterodine Tartrate | 2015 |
Muscarinic Receptor Binding in Rat Bladder Urothelium and Detrusor Muscle by Intravesical Solifenacin.
Topics: Administration, Intravesical; Animals; Benzilates; Male; Mandelic Acids; Muscarinic Antagonists; Muscle, Smooth; Nortropanes; Rats, Sprague-Dawley; Receptors, Muscarinic; Solifenacin Succinate; Urinary Bladder; Urological Agents; Urothelium | 2016 |
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Severity of Illness Index; Solifenacin Succinate; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Vision Disorders; Xerostomia; Young Adult | 2018 |
Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Topics: Adolescent; Adult; Cholinergic Antagonists; Female; Humans; Male; Mandelic Acids; Medication Adherence; Middle Aged; Obesity; Quality of Life; Sex Factors; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive; Young Adult | 2017 |
Overactive bladder - pharmacological treatment.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Antidepressive Agents; Benzilates; Benzofurans; Brazil; Clinical Decision-Making; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Pyrrolidines; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2019 |
A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzofurans; Denmark; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Norway; Practice Patterns, Physicians'; Prospective Studies; Pyrrolidines; Registries; Solifenacin Succinate; Sweden; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2019 |
Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Topics: Aged; Canada; Case-Control Studies; Dementia; Humans; Muscarinic Antagonists; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2022 |
[Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
Topics: Acetanilides; Humans; Muscarinic Antagonists; Prescriptions; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents | 2023 |